Dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist. Displays antiParkinsonian activity.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 282.23. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.54 mL||17.72 mL||35.43 mL|
|5 mM||0.71 mL||3.54 mL||7.09 mL|
|10 mM||0.35 mL||1.77 mL||3.54 mL|
|50 mM||0.07 mL||0.35 mL||0.71 mL|
References are publications that support the biological activity of the product.
Robertson et al (1993) In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J.Pharmacol.Exp.Ther. 264 1344 PMID: 8095550
Nishio et al (1996) 5-HT3 receptor blocking properties of the antiParkinsonian agent, talipexole. Gen.Pharmacol. 27 779 PMID: 8842679
Ricci and Taira (1999) Adrenoceptor involvement in the cardiovascular responses to B-HT 920 in sinoaortic denervated rats. Gen.Pharmacol. 32 29 PMID: 9888250
Maina and Mathews (2010) A functional fast scan cyclic voltammetry assay to characterize dopamine D2 and D3 autoreceptors in the mouse striatum. ACS Chem.Neurosci. 1 450 PMID: 20567609
If you know of a relevant reference for B-HT 920, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: B-HT 920, B-HT 920 supplier, 5-HT3, antagonists, D2, α2-adrenoceptor, alpha2-adrenoceptor, a2-adrenoceptor, a2-adrenergic, agonists, receptor, Serotonin, Receptors, Dopamine, dopaminergic, B-HT920, Talipexole, Adrenergic, Alpha-2, 2759, Tocris Bioscience
1 Citation for B-HT 920
Citations are publications that use Tocris products. Selected citations for B-HT 920 include:
Otvos et al (2015) Development of Plate Reader and On-Line Microfluidic Screening to Identify Ligands of the 5-Hydroxytryptamine Binding Protein in Venoms. Autophagy 7 2336 PMID: 26114334
Do you know of a great paper that uses B-HT 920 from Tocris? Please let us know.
Reviews for B-HT 920
There are currently no reviews for this product. Be the first to review B-HT 920 and earn rewards!
Have you used B-HT 920?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.